BSE Live
Mar 12, 16:01Prev. Close
1403.75
Open Price
1395.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 12, 15:56Prev. Close
1404.70
Open Price
1392.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Dr Lal PathLabs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 492.25 | 362.29 | 241.08 | 350.29 | 296.48 | |
| Net CashFlow From Operating Activities | 568.89 | 535.33 | 456.03 | 446.69 | 398.15 | |
| Net Cash Used In Investing Activities | -303.16 | -24.27 | -287.31 | -449.25 | -212.02 | |
| Net Cash Used From Financing Activities | -334.03 | -413.86 | -283.18 | 136.45 | -138.56 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -68.31 | 97.20 | -114.46 | 133.90 | 47.58 | |
| Cash And Cash Equivalents Begin of Year | 360.93 | 263.73 | 378.20 | 244.30 | 196.72 | |
| Cash And Cash Equivalents End Of Year | 292.63 | 360.93 | 263.73 | 378.20 | 244.30 |
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
09.03.2026
06.03.2026
06.03.2026
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
05.02.2026
Dr Lal PathLab Consolidated December 2025 Net Sales at Rs 659.80 crore, up 10.57% Y-o-Y
03.02.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
10.11.2025
Dr Lal PathLab Standalone September 2025 Net Sales at Rs 699.60 crore, up 19.82% Y-o-Y
12.03.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
05.02.2026
Dr Lal PathLab Consolidated December 2025 Net Sales at Rs 659.80 crore, up 10.57% Y-o-Y
03.02.2026
Dr Lal PathLab Standalone December 2025 Net Sales at Rs 632.10 crore, up 19.69% Y-o-Y
10.11.2025
Dr Lal PathLab Standalone September 2025 Net Sales at Rs 699.60 crore, up 19.82% Y-o-Y
06.10.2021
Dr. Lal PathLabs Q2 PAT seen up 28.4% YoY to Rs 112 cr: Prabhudas Lilladher
18.01.2021
Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher
11.10.2019
Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak
15.07.2019
Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities